ClinicalTrials.gg
CompletedNCT04856007Updated Apr 29, 2022

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

A Phase 1 interventional study of Dapagliflozin/metformin XR FDC 5/500 mg and Dapagliflozin/metformin XR FDC 10/1000 mg in Healthy Volunteer, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-29.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To assess the bioequivalence between dapagliflozin/metformin XR FDC tablet and co-administration of dapagliflozin and metformin XR tablets.

Read the detailed description

A Single-centre, Parallel-cohort, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Two Cohorts of Healthy Chinese Subjects in the Fed State.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Dapagliflozin
  • Forxiga
  • Metformin XR
  • Glucophage XR
  • Xigduo XR
  • Bioequivalence
  • Cross-over
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures.
  2. Healthy Chinese subjects as determined by no deviation from normal in medical history, vital signs, physical examination, 12-lead , and clinical laboratory evaluations.
  3. Male or female, ages 18 to 55 years, inclusive, at the time of signing the informed consent
  4. Weigh at least 50 kg (for male) and 45 kg (for female), respectively, and have a (BMI) ≥ 19 and \<26 kg/m2. BMI = weight (kg)/[height (m)]2.
  5. Female participants: Women of must use one highly effective form of .
  6. Must be able to communicate with the investigator, understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Any significant acute or chronic medical illness.
  2. Current or recent (within 3 months prior to study drug administration) gastrointestinal disease that may impact drug absorption and affect PK of the study drugs. Additionally, any gastrointestinal surgery (eg, partial gastrectomy, pyloroplasty) that could impact the absorption of study drug.
  3. Any major surgery, as determined by the investigator, within 4 weeks prior to study drug administration.
  4. Donation of blood within 3 months prior to study drug administration.
  5. Blood transfusion within 4 weeks prior to study drug administration.
  6. Inability to tolerate oral medication.
  7. Inability to tolerate venous access.
  8. Drug or alcohol abuse within 6 months prior to study drug administration. Alcohol abuse is defined as a history of regular alcohol consumption exceeding 14 drinks per week, or a positive breath alcohol test at screening and/or check-in. 1 drink equals to 5 ounces (150ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of hard liquor.
  9. Regularly drink more than 3 cups of coffee or other caffeine-containing products a day, or 5 cups of tea a day.
  10. Regular smoker (the subject should be able to abstain from smoking for the duration of the study without having abstinence, therefore they should not be regular smokers, regular smokers are defined as people who smoke everyday), use of tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 4 weeks prior to study drug administration .
  11. Any other sound medical, psychiatric and/or social reason as determined by the investigator.
  12. Any of the following on prior to study drug administration:

    1. PR≥210ms
    2. QRS≥120ms
    3. ≥500ms
    4. QTcF≥450ms(male) or QTcF≥470ms(female)
  13. Positive urine screen for drugs of abuse.
  14. Any abnormal findings in urinalysis (may repeat once) at screening, as judged by the investigator.
  15. Glucosuria at screening.
  16. Abnormal liver function tests ( [ALT], aspartate aminotransferase [AST], or total > 10% above [ULN]).
  17. Elevated serum creatinine (> ULN).
  18. Positive blood screen for antibody , Syphilis antibody, antibody , or surface antigen (HbsAg) or only Hepatitis B core antibody (anti-HBc) in Hepatitis B serologic test.
  19. History of allergy to SGLT2 inhibitor drug class or related compounds.
  20. History of allergy or intolerance to metformin or other similar acting agents.
  21. History of any significant drug allergy (such as anaphylaxis or hepatotoxicity).
  22. Prior exposure to metformin or dapagliflozin within 3 months of study drug administration.
  23. Exposure to any product or placebo within 4 weeks prior to study drug administration.
  24. Use of any prescription drugs or over-the counter (OTC), traditional Chinese medicine and herbal preparations within 4 weeks prior to study drug administration.
  25. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff or staff at the study site).
  26. Previous enrolled or randomized in the present study.
  27. For women only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding.
  28. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  29. Has clinical signs and symptoms consistent with COVID-19 infection (eg fever, dry cough, dyspnea, sore throat, fatigue.. etc) as judged by investigator or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission.
  30. History of COVID-19.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Dapagliflozin 5mg + Metformin 500mg XR

    co-administration of a single oral dose of a 5mg dapagliflozin (Forxiga® 5mg) tablet and a 500mg metformin XR (Glucophage XR®) tablet

    Drug: Dapagliflozin/metformin XR FDC 5/500 mg

  • Experimental
    Dapagliflozin/metformin XR FDC 5/500 mg

    single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR subject

    Drug: Dapagliflozin 5 mg + Metformin 500 mg XR

  • Experimental
    Dapagliflozin 10mg + Metformin 1000mg XR

    co-administration of a single oral dose of a 10mg dapagliflozin (Forxiga® 10mg) tablet and two 500mg metformin XR (Glucophage XR®) tablets

    Drug: Dapagliflozin/metformin XR FDC 10/1000 mg

  • Experimental
    Dapagliflozin/metformin XR FDC 10/1000 mg

    ingle FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR

    Drug: Dapagliflozin 10 mg + Metformin 1000 mg XR

Interventions

  • DrugDapagliflozin/metformin XR FDC 5/500 mg

    In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.

    Also known as: Xigduo XR

  • DrugDapagliflozin/metformin XR FDC 10/1000 mg

    In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.

    Also known as: Xigduo XR

  • DrugDapagliflozin 5 mg + Metformin 500 mg XR

    Drug page: Dapagliflozin

    In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.

    Also known as: Forxiga + Glucophage XR

  • DrugDapagliflozin 10 mg + Metformin 1000 mg XR

    Drug page: Dapagliflozin

    In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.

    Also known as: Forxiga + Glucophage XR

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from zero to the last quantifiable concentration(AUClast) of dapagliflozin and metformin.

    For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose.

    Time frame: From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

  2. Area under the plasma concentration-time curve from zero to infinity (AUCinf) of dapagliflozin and metformin.

    For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose.

    Time frame: From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

  3. Maximum observed plasma concentration (Cmax) of dapagliflozin and metformin.

    For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose.

    Time frame: From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

Secondary outcomes

  1. Time to maximum observed plasma concentration (tmax) of dapagliflozin and metformin.

    For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose.

    Time frame: From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

  2. Terminal elimination rate constant (λz) of dapagliflozin and metformin.

    For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose.

    Time frame: From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

  3. Half-life associated with terminal slope of a semi-logarithmic concentration-time curve(t½λz) of dapagliflozin and metformin.

    For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose.

    Time frame: From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

  4. Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of dapagliflozin and metformin.

    For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose.

    Time frame: From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

  5. Apparent volume of distribution following extravascular administration (Vz/F) of dapagliflozin and metformin.

    For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose.

    Time frame: From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

Other outcomes

  1. Haematology and clinical chemistry laboratory variables over time - SI unit - Change from baseline

    To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state.

    Time frame: Day 2 and Day 4 in Treatment period 1 and 2, respectively.

  2. Vital signs over time - Change from baseline

    To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state.

    Time frame: From Day 2 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

  3. ECG variables over time - Change from baseline

    To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state.

    Time frame: Day 1, 4 hours and 8 hours after dosing and Day 4 in Treatment period 1 and 2, respectively.

  4. Urinalysis data over time

    To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state.

    Time frame: Day 2 and Day 4 in Treatment period 1 and 2, respectively.

  5. Incidence of adverse events

    To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state.

    Time frame: From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days.

07

Study locations

1 site
  • Research Site
    Suzhou, 215006, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Jun 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2021
First posted
Apr 22, 2021
StartActual
Apr 12, 2021
Primary completionActual
Jun 14, 2021
CompletionActual
Jun 14, 2021
Last update
Apr 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04856007
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 22, 2021
Start date
Apr 12, 2021
Primary completion
Jun 14, 2021
Completion
Jun 14, 2021
Last update
Apr 29, 2022

Study contacts

Liyan Miao, MD
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion